



(12) Translation of
European patent specification

(11) NO/EP 2801580 B1

NORWAY

(19) NO
(51) Int Cl.
C07H 19/20 (2006.01)
A61K 31/7072 (2006.01)
A61P 31/00 (2006.01)

Norwegian Industrial Property Office


(45)	Translation Published	2024.01.02
(80)	Date of The European Patent Office Publication of the Granted Patent	2023.09.13
(86)	European Application Nr.	14169060.2
(86)	European Filing Date	2008.03.26
(87)	The European Application's Publication Date	2014.11.12
(30)	Priority	2007.03.30, US, 909315 P 2007.10.24, US, 982309 P 2008.03.21, US, 53015
(84)	Designated Contracting States:	AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MT ; NL ; NO ; PL ; PT ; RO ; SE ; SI ; SK ; TR
(62)	Divided application	EP2203462, 2008.03.26
(73)	Proprietor	Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, USA
(72)	Inventor	SOFIA, Michael, Joseph, 3066 Antler Road, Doylestown, PA Pennsylvania 18902, USA DU, Jinfa, 1206 Reins Circle, New Hope,, PA Pennsylvania 18938, USA WANG, Peiyuan, 20 Radburn Road, Glen Rock, NJ New Jersey 07452, USA NAGARATHNAM, Dhanapalan, 52 Virginia Rail Drive, 06524, CT Connecticut Bethany, USA
(74)	Agent or Attorney	AWA NORWAY AS, Postboks 1052 Hoff, 0218 OSLO, Norge

(54)	Title	Nucleoside phosphoramidate prodrugs
(56)	References Cited:	WO-A2-2005/003147 WO-A2-2008/085508 US-A1- 2006 241 064 CLARK J L ET AL: "Design, synthesis, and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methylcytidine, a potent inhibitor of hepatitis C virus replication", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 48, 1 January 2005 (2005-01-01), pages 5504-5508, XP002415215, ISSN: 0022-2623, DOI: 10.1021/JM0502788 CLARK J L ET AL: "Synthesis and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methyl purine nucleosides as inhibitors of hepatitis C virus RNA replication", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 16, no. 6, 15 March 2006 (2006-03-15) , pages 1712-1715, XP027966449, ISSN: 0960-894X [retrieved on 2006-03-15]

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Forbindelse representert ved formel




for anvendelse ved behandling av en virusinfeksjon.

2. Forbindelse for anvendelse ifølge krav 1, hvor infeksjonen er en infeksjon med hepatitt C-virus, Vestnilvirus, gulfebervirus, denguevirus, rhinovirus, polio-virus, hepatitt A-virus, bovint viralt diarévirus eller Japansk encefalittvirus.


3. Forbindelse for anvendelse ifølge krav 2, hvor infeksjonen er en infeksjon med hepatitt C-virus.

4. Forbindelse for anvendelse ifølge krav 2 eller krav 3, hvor forbindelsen representert ved formel




administreres samtidig med et annet antiviralt middel valgt fra gruppen bestående av interferon- α , interferon- β , pegylert interferon- α , ribavirin, levovirin og viramidin.

5. Anvendelse av en forbindelse representert ved formel





for fremstilling av et legemiddel for behandling av en infeksjon med hepatitt C-virus, Vestnilvirus, gulfebervirus, denguevirus, rhinovirus, poliovirus, hepatitt A-virus, bovint viralt diarévirus eller Japansk encefalittvirus.

- 5 6. Anvendelse ifølge krav 5, hvor infeksjonen er en infeksjon med hepatitt C-virus.
7. Fremgangsmåte for fremstilling av en forbindelse representert ved formel



Hvilken fremgangsmåte omfatter å:

- 10 omsette en forbindelse 4'' med en nukleosidanalogs 5'



hvor X' er en utgående gruppe.